Étiquette : ptsd

Deconstructing Ecstasy : The Politics Of MDMA Research, Charles S. Grob, 2000

Deconstructing Ecstasy : The Politics Of MDMA Research Charles S. Grob Addiction Research, 2000, 8, 6, 549-588 http://dx.doi.org/10.3109/16066350008998989   What is Ecstasy? Defined by the New Webster’s Dictionary as a state of intense overpowering emotion, a condition of exultation or mental rapture induced by beauty, music, artistic creation or the contemplation of the divine, ecstasy derives etymologically from the ancient Greek ekstasis, which means flight of the soul from the body. The anthropologist, Mircea Eliade, who explored the roots of religious experience in his book Shamanism: Archaic Techniques of Ecstasy, has described the function of this intense state of mind among aboriginal peoples. Select individuals are [...]

Lire la suite

The Divergent Effects of CDPPB and Cannabidiol on Fear Extinction and Anxiety in a Predator Scent Stress Model of PTSD in Rats, John Shallcross et al., 2019

The Divergent Effects of CDPPB and Cannabidiol on Fear Extinction and Anxiety in a Predator Scent Stress Model of PTSD in Rats John Shallcross, Peter Hámor, Allison R. Bechard, Madison Romano, Lori Knackstedt and Marek Schwendt Frontiers in Behavioral Neuroscience, May 2019 | Volume 13 | Article 91 ORIGINAL RESEARCH published: 10 May 2019 doi: 10.3389/fnbeh.2019.00091 Post-traumatic stress disorder (PTSD) currently has no FDA-approved treatments that reduce symptoms in the majority of patients. The ability to extinguish fear memory associations is impaired in PTSD individuals. As such, the development of extinction-enhancing pharmacological agents to be used in combination with exposure therapies may benefit the treatment of [...]

Lire la suite

La psychothérapie psychédélique est de retour, Stéphanie Chayet, M Le Magazine du Monde, 2015

La psychothérapie psychédélique est de retour M le magazine du Monde | 12.03.2015   Mescaline, ecstasy, psilocybine soigneront-ils la dépression, l’angoisse, l’autisme ou l’alcoolisme ? Des psychiatres américains explorent le potentiel thérapeutique de ces substances illicites. Par Stéphanie Chayet Engourdissement, d’abord. Puis grande fatigue, bâillements. Des images, très abstraites, comme de l’art moderne. Des motifs. Image d’un chat en train de mordiller le câble de freinage d’un vélo. Après ça ? Sentiment de ne pas ­m’aimer. Pas du tout. Puis je me demande : pourquoi je ne m’aimerais pas ? Il n’y a aucune raison. » Ainsi commence, mot pour mot, le « compte rendu d’expérience [...]

Lire la suite

LSD : le retour de l’enfant terrible, Didier Acier, Laviedesidées.fr, 2015

LSD : le retour de l’enfant terrible par Didier ACIER pour laviedesidees.fr, https://laviedesidees.fr/LSD-le-retour-de-l-enfant-terrible.html 6 mars 2015 Indissociable du mouvement hippie, l’usage récréatif de LSD-25 a donné lieu à l’interdiction précoce de ce médicament. Le potentiel psychothérapeutique de l’acide lysergique diéthylamide est pourtant bien établi, notamment en matière de soins palliatifs, et l’on peut souhaiter que l’exploration scientifique et médicale de ce produit se développe à l’avenir. Genèse d’un médicament Printemps 1943 en Suisse, à Bâle. Albert Hoffmann, chimiste de son état, synthétise pour la compagnie Sandoz, des alcaloïdes, à partir de l’ergot de seigle. Sa recherche vise à développer de nouveaux médicaments. Alors qu’il travaille sur l’acide [...]

Lire la suite

Du LSD ou de l’ecstasy pour traiter la maladie mentale, Alexis Riopel, Ledevoir.com, 2018

Du LSD ou de l’ecstasy pour traiter la maladie mentale La thérapie psychédélique a pour principe d’aider les gens à adopter un nouveau regard sur leur santé et leur mode de vie. Alexis Riopel 10 décembre 2018 https://www.ledevoir.com/societe/sante/543271/science-du-lsd-ou-de-l-ecstasy-pour-traiter-la-maladie-mentale   Un cachet, une séance, des effets qui perdurent. Grosso modo, telle est la promesse des psychiatres qui travaillent sur le développement de traitements recourant à des drogues psychédéliques pour soigner des troubles de santé mentale. Plutôt que d’apaiser les symptômes de la maladie mentale, ces substances servent à « reconnecter » le cerveau. Si elles étaient légalisées dans un contexte médical — et c’est ce qui semble en [...]

Lire la suite

Cannabidiol regulation of emotion and emotional memory processing : relevance for treating anxiety-related and substance abuse disorders, Jonathan L.C. Lee et al., 2017

Cannabidiol regulation of emotion and emotional memory processing : relevance for treating anxiety-related and substance abuse disorders Jonathan L.C. Lee, Leandro J. Bertoglio, Francisco S. Guimarães and Carl W. Stevenson British Journal of Pharmacology, 2017, 174, 3242–3256 DOI : 10.1111/bph.13724 Abstract Learning to associate cues or contexts with potential threats or rewards is adaptive and enhances survival. Both aversive and appetitive memories are therefore powerful drivers of behaviour, but the inappropriate expression of conditioned responding to fear- and drug-related stimuli can develop into anxiety-related and substance abuse disorders respectively. These disorders are associated with abnormally persistent emotionalmemories and inadequate treatment, often leading to symptom relapse. [...]

Lire la suite

Cannabidiol as a Potential Treatment for Anxiety Disorders, Blessing E.M. et al., 2015

Cannabidiol as a Potential Treatment for Anxiety Disorders. Blessing E.M.; Steenkamp M.M.; Manzanares J.; Marmar C.R. Neurotherapeutics, 2015, 12, 4, 825-36 doi:10.1007/s13311-015-0387-1 (ISSN: 1878-7479)   Abstract : Cannabidiol (CBD), a Cannabis sativa constituent, is a pharmacologically broad-spectrum drug that in recent years has drawn increasing interest as a treatment for a range of neuropsychiatric disorders. The purpose of the current review is to determine CBD's potential as a treatment for anxiety-related disorders, by assessing evidence from preclinical, human experimental, clinical, and epidemiological studies. We found that existing preclinical evidence strongly supports CBD as a treatment for generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive-compulsive disorder, [...]

Lire la suite

MDMA-assisted psychotherapy for treatment of PTSD : study design and rationale for phase 3 trials based on pooled analysis of sixphase 2 randomized controlled trials, Michael C. Mithoefer et al., 2019

MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials Michael C. Mithoefer, Allison A. Feduccia, Lisa Jerome, Anne Mithoefer, Mark Wagner, Zach Walsh, Scott Hamilton, Berra Yazar-Klosinski, Amy Emerson, Rick Doblin Psychopharmacology, 2019 https://doi.org/10.1007/s00213-019-05249-5 Abstract Background : Posttraumatic stress disorder is a prevalent mental health condition with substantial impact on daily functioning that lacks sufficient treatment options. Here we evaluate six phase 2 trials in a pooled analysis to determine the study design for phase 3 trials of MDMA-assisted psychotherapy for PTSD. Methods : Six randomized, double-blind, controlled clinical trials [...]

Lire la suite

3,4-Methylenedioxymethamphetamine assisted psychotherapy for treatment of chronic posttraumatic stress disorder : A randomized phase 2 controlled trial, Marcela Ot’alora G et al., 2018

3,4-Methylenedioxymethamphetamine assisted psychotherapy for treatment of chronic posttraumatic stress disorder : A randomized phase 2 controlled trial Marcela Ot’alora G, Jim Grigsby, Bruce Poulter1, Joseph W Van Derveer III, Sara Gael Giron, Lisa Jerome, Allison A Feduccia, Scott Hamilton, Berra Yazar-Klosinski, Amy Emerson, Michael C Mithoefer and Rick Doblin Journal of Psychopharmacology, 2018, 1-13 Doi : 10.1177/0269881118806297   Abstract Background : Posttraumatic stress disorder often does not resolve after conventional psychotherapies or pharmacotherapies. Pilot studies have reported that 3,4-methylenedioxymethamphetamine (MDMA) combined with psychotherapy reduces posttraumatic stress disorder symptoms. Aims : This pilot dose response trial assessed efficacy and safety of MDMA-assisted psychotherapy across multiple therapy teams. Methods : [...]

Lire la suite

A Review of 3,4-methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy, Ben Sessa, 2019

A Review of 3,4-methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy Ben Sessa, Laurie Higbed and David Nutt Frontiers in Psychiatry, 2019, Vol. 10, article 138 DOI : 10.3389/fpsyt.2019.00138 Neuropsychopharmacology Unit, Department of Medicine, Imperial College London, London, United Kingdom   Abstract : This paper provides a brief review of the history, proposed pharmacological mechanisms, safety issues, and clinical applications of the medicine 3,4-methylenedioxymethamphetamine (MDMA). Most clinical MDMA research in patients to date has focused on MDMA-assisted psychotherapy to treat posttraumatic stress disorder (PTSD). In this review paper other potential therapeutic applications for MDMA therapy are described, including contemporary studies treating anxiety associated with autism and the authors’ ongoing study exploring the potential [...]

Lire la suite